PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of Staphylococcus aureus. 2020

Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

Pregnadiene-11-hydroxy-16α,17α-epoxy-3,20-dione-1 (PYED-1), a heterocyclic corticosteroid derivative of deflazacort, exhibits broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria. Here, we investigated the effect of PYED-1 on the biofilms of Staphylococcus aureus, an etiological agent of biofilm-based chronic infections such as osteomyelitis, indwelling medical device infections, periodontitis, chronic wound infections, and endocarditis. PYED-1 caused a strong reduction in biofilm formation in a concentration dependent manner. Furthermore, it was also able to completely remove the preformed biofilm. Transcriptional analysis performed on the established biofilm revealed that PYED-1 downregulates the expression of genes related to quorum sensing (agrA, RNAIII, hld, psm, and sarA), surface proteins (clfB and fnbB), secreted toxins (hla, hlb, and lukD), and capsular polysaccharides (capC). The expression of genes that encode two main global regulators, sigB and saeR, was also significantly inhibited after treatment with PYED-1. In conclusion, PYED-1 not only effectively inhibited biofilm formation, but also eradicated preformed biofilms of S. aureus, modulating the expression of genes related to quorum sensing, surface and secreted proteins, and capsular polysaccharides. These results indicated that PYED-1 may have great potential as an effective antibiofilm agent to prevent S. aureus biofilm-associated infections.

UI MeSH Term Description Entries

Related Publications

Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
April 2015, FEMS microbiology letters,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
April 2023, Pharmaceuticals (Basel, Switzerland),
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
January 2018, Frontiers in microbiology,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
February 2022, iScience,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
June 2021, ACS infectious diseases,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
January 2021, Frontiers in microbiology,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
May 2010, Nature,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
December 2015, Antimicrobial agents and chemotherapy,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
January 2020, Journal of traditional medicine & clinical naturopathy,
Adriana Vollaro, and Anna Esposito, and Eliana Pia Esposito, and Raffaele Zarrilli, and Annalisa Guaragna, and Eliana De Gregorio
May 2023, Bioscience, biotechnology, and biochemistry,
Copied contents to your clipboard!